Published

Explainable AI framework for psilocybin depression treatment optimization

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in Computer Science
Date: 2026-03-16
Source: Crossref
DOI: 10.3389/fcomp.2025.1652190
PubMed: Unavailable

Authors

Sungheetha Akey Rajesh Sharma R.Aroba Oluwasegun Julius Mahapatra Sheila Mahendhiran P. D.

Watch author

Derived topics and classifications

psilocybin Depression Brain Imaging Pharmacology Receptor Pharmacology Aging Clinical Trial Randomized Controlled Trial Safety Randomized Controlled Trial

Citation graph

40 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.48550/arxiv.1810.03292 10.1136/bmj.309.6947.102 10.1214/09-ss054 10.1177/0962280214558972 10.1038/s41598-020-59282-y 10.1001/jama.2017.18391 10.1111/j.2517-6161.1995.tb02031.x 10.1007/978-3-540-24775-3_3 10.3310/hta3090 10.1175/1520-0493(1950)078<0001:vofeit>2.0.co;2 10.1007/s40262-017-0540-6 10.1137/0916069

Indexed papers citing this DOI

Explainable AI framework for psilocybin depression treatment optimization2026-03-16

Related papers

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24 Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2020-12-01 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10